Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based President operating in the Medical Device space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Jeanne Bolger
Vice President Venture Investing of Johnson & Johnson Development Corporation
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Follow Jeanne Bolger:
About Johnson & Johnson Development Corporation, Pulmocide: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Nina Kataria
Senior Vice President, Global Human Resources of Circassia
Nina Kataria joined Circassia in June 2014 to lead the company’s HR function. She brings to Circassia over 25 years’ experience of Human Resources, and has significant experience of the life sciences industry. Most recently, she was Human Resources Director at Lonza Biologics PLC, where she had strategic and operational responsibilities in the UK and internationally. Previously, she was the UK Human Resources Manager at Innovex (part of Quintiles), following roles of increasing responsibility at companies that are now part of Toyota and Unilever. She is a Fellow of the Chartered Institute of Personnel and Development (CIPD) and holds a post-graduate diploma from the Institute. She graduated from Thames Valley University in Business and Finance.
Follow Nina Kataria:
About Chartered Institute of Personnel and Development, Circassia: Circassia is dedicated to point of care asthma diagnosis and management.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
William Richardson
Executive Vice President of Savaria Corp
Follow William Richardson:
About Savaria Corp: Savaria provides accessibility solutions for the elderly and physically challenged to increase their mobility and independence.
Nick Child
Vice President of Stablepharma Ltd
Nick Child – Vice President & Co Founder Experienced company leader, business developer, multi-disciplined & experienced in UK & International markets, manufacturing & distribution. Initiated various start-ups, acquisitions, & funding rounds.
Follow Nick Child:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Paul Marcun
Executive Vice President, Chronic Care of Coloplast Denmark
Paul Marcun is the Executive Vice President of Chronic Care at Coloplast.
Follow Paul Marcun:
About Coloplast Denmark: Coloplast is a Danish company that develops and markets products and services related to ostomy, urology, continence, and wound care.
Clive Morris
President & Chief Executive Officer of Inivata
Follow Clive Morris:
About Inivata: Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
Bryan Olin
Senior Vice President of LivaNova
Bryan Olin, PhD is the Senior Vice President, Clinical, Quality & Regulatory Affairs at LivaNova. Dr. Olin joined Cyberonics in May 2009 as Vice President, Quality. In August 2009, he assumed additional responsibility for Clinical Affairs, and in April 2011, his responsibilities were expanded again to include Regulatory Affairs. With the 2015 merger between Cyberonics and Sorin, his responsibilities expanded to include corporate-wide responsibilities for the clinical, quality and regulatory affairs functions at LivaNova. Prior to May 2009, Dr. Olin was employed at Zeltiq Aesthetics, Inc., a privately held medical technology company in the San Francisco area, where he served as Sr. Director, Quality Assurance since October 2007. Prior to Zeltiq Aesthetics, Dr. Olin was employed at the LifeScan and Cordis companies of Johnson & Johnson from 1999 to 2007, holding several positions of increasing responsibility in quality assurance, statistics and clinical data management. Dr. Olin began his career with Procter & Gamble in 1993 after obtaining his Ph.D. in Statistics from Iowa State University. He currently serves on the board of directors for the Medical Devices Innovation Consortium (MDIC) and as an industry representative on the Advisory Committee for The National Patient-Centered Clinical Research Network (PCORnet).
Follow Bryan Olin:
About LivaNova: LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment.
Brad Bailey
Vice President of Sales of Ivy Sports Medicine
Brad Bailey, Vice President of Sales brings over 19 years of experience in the medical device industry with a focus in Sales management and Marketing. He has extensive experience in building teams to execute sucessful product launches and realize sustained sales growth. Mr. Bailey has worked in and run sales organizations focusing in Sports Medicine, he was Director of Sales of the Sports Tissue and Biologics Division at ConMed Corportation. He has also held leadership positions with the Musculoskeletal Transplant Foundation (MTF), DePuy Spine and Spar Medical. Mr. Bailey graduated from Birmingham Southern College in 1993 with a B.S. in Management.
Follow Brad Bailey:
About Ivy Sports Medicine: Ivy Sports Medicine is a young, dynamic company with extensive expertise in the development and production of meniscus implants.
Jerome Declerck
Vice President Research & Develop,ment of Optellum
Follow Jerome Declerck:
About Optellum: Optellum develops an imaging biomarker for smart lung cancer detection.
